当前位置: 首页 >> 检索结果
265. Clinical Outcomes in Patients With COPD With Disease Stability: Data from the Korea COPD Subgroup Study Cohort.
作者: Eunjeong Son.;Hyewon Seo.;Seung Won Ra.;Seoung Ju Park.;Soo-Jung Um.;Seong Yong Lim.;Hyoung Kyu Yoon.;Kwang Ha Yoo.;Joon Young Choi.;Chin Kook Rhee.
来源: Chest. 2025年
COPD is a heterogeneous disease with progressive airflow limitation. Despite therapeutic advances, current treatments poorly halt COPD progression. Disease stability (DS) is a proposed treatment goal, but its clinical significance remains uncertain.
267. Adjunctive Corticosteroid Use and Clinical Outcomes in Non-HIV Pneumocystis jirovecii Pneumonia.
作者: Aaron M Pulsipher.;Holenarasipur R Vikram.;Michael B Gotway.;Rodrigo Cartin-Ceba.;Emily R Thompson.;Andrew H Limper.;Ayan Sen.;Augustine Lee.;Kealy Ham.
来源: Chest. 2026年169卷3期616-625页
Adjunctive corticosteroids improve outcomes in HIV-associated Pneumocystis jirovecii pneumonia (PCP), but their role in non-HIV-associated PCP is uncertain. Prior evidence largely has been limited to binary treatment groups and rarely has accounted for daily or cumulative dose effects.
268. Geographical Variations in CPAP Termination Rates in Patients With OSA: Insights From the Nationwide Claims Data Lake for Sleep Apnoea (ALASKA) French Nationwide Data Set.
作者: Sébastien Bailly.;Guillaume Deltreil.;Florent Lavergne.;Renaud Tamisier.;Sébastien Baillieul.;Jean Louis Pépin.
来源: Chest. 2025年 269. Examining the Threat of H5N1 Highly Pathogenic Avian Influenza to Human Health.
作者: Juliette Blais-Savoie.;Emily Halajian.;Kuganya Nirmalarajah.;Andra Banete.;Juan C Corredor.;Jonathon D Kotwa.;Yaejin Lee.;Sugandha Raj.;Shayan Sharif.;Nicole Mideo.;Samira Mubareka.
来源: Chest. 2025年
The clade 2.3.4.4b highly pathogenic avian influenza (HPAI) virus H5N1 is the etiologic agent for an ongoing panzootic with a rapidly increasing number of human infections. Although morbidity and mortality in humans with this clade seems to be limited to date, previous HPAI H5N1 viruses have been associated with mortality rates of approximately 50% in humans. Not all cases of clade 2.3.4.4b influenza A(H5N1) HPAI in humans have been associated with known exposure to infected animals. Therefore, clinicians must be aware of the changing viral ecology, human risk factors, and clinical presentations associated with H5N1 viruses to facilitate early case recognition and management of clade 2.3.4.4b A(H5N1) HPAI infection in humans.
270. Growth Differentiation Factor-15 Improves Prognostic Accuracy of Risk Stratification in Pulmonary Arterial Hypertension.
作者: An-Yi Wang.;Jie-Ling Ma.;Yue Cui.;Bao-Chen Qiu.;Chao Liu.;Dan Lu.;Yin-Jian Yang.;Yu-Ping Zhou.;Ze-Jian Zhang.;Xi-Qi Xu.;Xin Jiang.;Tian-Yu Lian.;Chun-Yan Cheng.;Kai Sun.;Pei-Wen Wang.;Yue-Jiao Ma.;Zhi-Cheng Jing.
来源: Chest. 2026年169卷3期758-768页
The etiology of pulmonary arterial hypertension (PAH) is complex and the risk is heterogeneous. Growth differentiation factor-15 (GDF-15) has been reported to be associated with the prognosis of patients with PAH, but whether the use of GDF-15 as an additional prognostic biomarker can improve preexisting PAH risk stratification remains unclear.
271. A National Evaluation of Intercostal Chest Drain Removal Strategies.
作者: Niki Veale.;Anthony W Martinelli.;Dheeraj Sethi.;Phillip De Souza.;Khaing Zar Mon.;Joyce Oi Suet Cheng.;David Morrow.;May Sam.;Irfan Saleem.;Kay Por Yip.;Jennifer Kerks.;David Henshall.;Tobias Smitherman-Cairns.;Katherine Smith.;Daniel Mitchell.;Karl Jackson.;Benjamin Pippard.;Seemab Paul.;Waheed Mohammad.;James Hyman.;Benjamin Rowlands.;Samantha Bosence.;Catharine Pearce.;Ben Probyn.;Richard Thorley.;Matthew Mitchell.;Andrew Griffiths.;Richard Westley.;Abdullah Bin Huda.;Asim Mehmood.;Abid Khan.;Vern Tee.;Rachel Crooks.;Paul Minnis.;Lewis Standing.;Wei Hann Ong.;M Salman Rashid.;Ahmed Salih.;Eve Lynn Koh.;Ching Khai Ho.;Yiwen Soo.;Matthew Hayes.;Clodagh Holmes.;Fatima Al-Arrayed.;Abeer Saad.;Beenish Iqbal.;Sam Trewick.;Patrick Goodley.;Jonathan Oldershaw.;Elizabeth Thompson.;Alexandra Hodge.;Mohamed Gadallah.;Rahul Bhat.;Eleanor Barton.;Anand Sundaralingam.;Osei Kankam.;James Quinn.;John P Corcoran.;Steven P Walker.;Avinash Aujayeb.;Jurgen Herre.;Akhilesh Jha.;Stefan J Marciniak.;Najib M Rahman.;Rob J Hallifax.
来源: Chest. 2026年169卷3期849-858页
Management of spontaneous pneumothorax often involves intercostal chest drain (ICD) insertion. Determining when to remove the ICD is controversial, with significant variation in practice. Establishing optimal ICD management in pneumothorax could reduce morbidity and improve cost-effectiveness.
273. Impact of Elevated Pulmonary Arterial Wedge Pressure on Safety and Efficacy of Balloon Pulmonary Angioplasty in the Treatment of Chronic Thromboembolic Pulmonary Hypertension.
作者: Piotr Szwed.;Paweł Kurzyna.;Marta Banaszkiewicz.;Piotr Kędzierski.;Michał Łomiak.;Rafał Wolański.;Marcin Wasilewski.;Michał Florczyk.;Michał Piłka.;Adam Torbicki.;Marcin Kurzyna.;Szymon Darocha.
来源: Chest. 2026年169卷2期498-508页
Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare condition caused by thromboembolic occlusions of the pulmonary arteries and characterized by elevated pulmonary pressure, vascular remodelling, and right ventricular overload, which can be treated effectively with balloon pulmonary angioplasty (BPA). The study aimed to evaluate whether elevated pulmonary arterial wedge pressure (PAWP), associated with left ventricular dysfunction, influences the effectiveness and safety of BPA treatment.
274. Post-ICU Care Trajectories and Outcomes Among Veterans: Comparing Veterans Affairs and Community Hospital Discharges.
作者: Zachary Hahn.;Hiam Naiditch.;Martha F Brucato.;Victor Talisa.;Brian Tyler.;John R Hotchkiss.;Sachin Yende.;Bryan J McVerry.;Florian B Mayr.
来源: Chest. 2025年
Survivors of critical illness face fragmented care transitions, leading to readmissions, emergency care use, and death. The Veterans Affairs (VA) Patient Aligned Care Team model emphasizes coordinated outpatient follow-up, yet many veterans now receive VA-purchased intensive care at community hospitals, potentially disrupting continuity.
275. Relationship Between Framingham 10-Year Cardiovascular Disease Risk Score and Pulse Wave Amplitude Drop Characteristics in a Sleep Clinic Cohort.
作者: Glenn M Stewart.;Benjamin K Tong.;Philip de Chazal.;Joanne Flood.;Yu Sun Bin.;Kristina Kairaitis.;John R Wheatley.;Andrew S L Chan.;Amanda J Piper.;Brendon J Yee.;Peter A Cistulli.; .
来源: Chest. 2026年169卷2期514-526页
Pulse oximetry-derived measures of autonomic vascular re-activity during sleep, quantified by pulse wave amplitude drop (PWAD) characteristics such as the PWAD index, have recently been proposed as a biomarker of cardiovascular disease (CVD) outcomes in patients with OSA.
276. Serial MRI Measures Short-Term Parenchymal Changes in Neonatal Bronchopulmonary Dysplasia.
作者: Samal Munidasa.;Nara S Higano.;Matthew M Willmering.;Abdullah S Bdaiwi.;Xavier Hoyos Cordon.;Daniela Bullard Elias.;Robert J Fleck.;Paul S Kingma.;Erik B Hysinger.;Jason C Woods.
来源: Chest. 2025年
Bronchopulmonary dysplasia (BPD) is the most common neonatal lung parenchymal disease characterized by obstructive and restrictive lung abnormalities. Evaluation of neonatal BPD lung disease using MRI has been shown to be more sensitive to short-term outcomes than standard clinical measures. However, the longitudinal trajectory of parenchymal disease remains poorly characterized.
277. Cardiovascular Events in COPD: Complementary Role of Cardiac Risk and Coronary Artery Calcium Scores.
作者: Juan P de-Torres.;Ciro Casanova.;Jorge Zagaceta.;José M Marín.;Carlos Cabrera.;Ana Ezponda.;Arantza Campo.;Ana Belén Alcaide.;Luis Seijo.;Gorka Bastarrika.;Victor Pinto-Plata.;Miguel Divo.;Bartolome R Celli.
来源: Chest. 2026年169卷3期631-640页
Patients with COPD are at high risk of major adverse cardiovascular events (MACEs) developing. Existing clinical tools for risk stratification in these patients have underperformed in predicting the outcomes.
279. Long-Term Major Respiratory Mortality Among 5-Year Survivors of Adolescent and Young Adult Cancer.
Adolescent and young adults (AYAs) diagnosed with cancer are at risk of experiencing pulmonary dysfunction years or even decades following completion of treatment.
|